Glenmark recalls 6,528 bottles of BP drug in US

Glenmark Pharmaceuticals is recalling 6,528 bottles of Diltiazem Hydrochloride extended-release capsules, a medication used to treat high blood pressure in the American market due to failed dissolution specifications, informed USFDA in its latest Enforcement Report.

The affected lot has been produced in India and is being recalled for “failed dissolution specifications”, the USFDA said.

“Out of Specification (OOS) was reported in a test of dissolution at the 12th month time point in long-term stability study,” it noted.

Glenmark initiated Class II recall of the drug across the US on March 26 this year.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Related Posts

  • Pharma
  • June 24, 2025
  • 80 views
Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal…

  • Pharma
  • June 24, 2025
  • 81 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma launches TEVIMBRA in India

Glenmark Pharma launches TEVIMBRA in India

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug